NCT02422485View on ClinicalTrials.gov

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Progressive Supranuclear Palsy
Interventions
DRUG

Salsalate

Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.

Trial Locations (2)

94158

University of California, San Francisco, San Francisco

97239

OHSU Parkinson Center & Movement Disorder Program, Portland

All Listed Sponsors
lead

Adam Boxer

OTHER

NCT02422485 - A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy | Biotech Hunter | Biotech Hunter